# Cipher Gene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cipher-gene

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.ciphergene.com
- Total disclosed funding: $31M
- Latest round: Series C (May 27, 2024)
- Investors on record: 12

## About

Established in 2015 and based in Beijing, China, Cipher Gene LLC is a biotech company that focuses on the analysis of big data in the field of children's genetic diseases. The company has production and operation centers, as well as a high-throughput drug screening R&D center in the Yangtze River Delta region. With a team of researchers from institutions such as Harvard University and the National Institutes of Health, Cipher Gene has a background in clinical molecular genetics. The CEO, Dr. Wei Shi, holds a Ph.D. in Biomedicine from East China Normal University and has served as a scientist at the National Cancer Institute of the NIH. The company has established stable cooperative relationships with over 300 medical and research institutions, including Peking University First Hospital and Xiangya Hospital of Central South University. Meanwhile, the company has completed nearly 70 international academic papers and obtained more than 150 patents and intellectual property rights, and has received honors including being named as a "High-tech Enterprise". In May 2024, it raised CNY 100 million in a round of series C funding.

The company focuses on the research and development of clinical diagnostic and prevention products for genetic diseases, offering a series of solution from newborn screening to genetic disease diagnosis and functional validation. Specific products include NGS-type whole exome testing for genetic diseases, whole genome sequencing, and so on. Its iWES product significantly enhances the positive detection rate with zero false positives, and its high-throughput drug screening platform facilitates the development of precision treatment drugs. Cipher Gene also provides translational medicine services that bridge clinical practice with scientific research.

The company generates revenue by providing genetic testing solutions and precision medical services, as well as offering high-throughput drug screening and translational medicine services to clients in the healthcare and pharmaceutical industries.

The company will use the series C funding raised in May 2024 to promote the co-construction of hospital LDT laboratories, accelerate the landing of integrated genetic/rare disease solutions in healthcare organizations, and accelerate the development and registration of products for tertiary prevention and control of birth defects.

## Funding rounds

- Series C, May 27, 2024, $14M — Zhongxi Capital, Chengdu Jinjiang Investment & Development Group
- Series B, May 11, 2021, $16M — Sova Capital, TusStar, CS Capital, Tsinghua Innovation Ventures, Yuanhui Investment
- Series A, May 31, 2018 — Shenzhen Guozhong Venture Capital, Kingcaptial-TC, Chuangjian Capital
- Angel, Feb 1, 2016, $1.5M — Everest VC, Jiangmen Capital, Chuangjian Capital

## Investors

- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Angel
- Jiangmen Capital (https://capitalatlas.ai/funds/jiangmen-capital) — Angel
- Chuangjian Capital (https://capitalatlas.ai/funds/chuangjian-capital) — Angel, Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- Kingcaptial-TC (https://capitalatlas.ai/funds/kingcaptial-tc) — Series A
- Sova Capital (https://capitalatlas.ai/funds/sova-capital) — Series B
- TusStar (https://capitalatlas.ai/funds/tusstar) — Series B
- CS Capital — Series B
- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Series B
- Yuanhui Investment — Series B
- Zhongxi Capital (https://capitalatlas.ai/funds/zhongxi-capital) — Series C
- Chengdu Jinjiang Investment & Development Group — Series C